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ABSTRACT 
Atrial fibrillation and the risk of myocardial infarction 
: a nation-wide propensity-matched study 
 
Hye Young Lee 
 
Department of medicine 
The Graduate School, Yonsei University 
 
(Directed by Professor Boyoung Joung) 
 
Objective In addition to being an established complicating factor for myocardial infarction (MI), 
recent studies have revealed that atrial fibrillation (AF) increased risk of MI. This study is to 
evaluate the risk of MI associated with AF in general population. 
Methods We examine the association between AF and incident MI in 497,366 adults [mean age 
47.6 ± 14.3 years, 250,569 women (50.0%)] from the Korean National Health Insurance Service 
database, who were free of AF and MI at baseline. AF group (n=3,295) was compared with 
propensity matched no-AF group (n=13,159).  
Results Over 4.2 years of follow up, 137 MI events occurred. AF was associated with 3-fold 
increased risk of MI (HR, 3.1; 95% CI, 2.22-4.37) in both men (HR, 2.91; 95% CI 1.91-4.45) and 
women (HR, 3.52; 95% CI 2.01-6.17). The risk of AF-associated MI was higher in patients free 
of hypertension, diabetes, ischemic stroke, and dyslipidemia at baseline. The cumulative 
incidence of AF-associated MI was lower in patients on anticoagulant and statin therapies.  
Conclusions AF was associated with an increased risk of MI, with its incidence lower in 
anticoagulants and statin users. Our finding suggests that AF complications beyond stoke should 
extend to total mortality to include MI.  
--------------------------------------------------------------------------------------------------------------------- 
Key Words: atrial fibrillation, myocardial infarction, nation-wide cohort. 
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I. INTRODUCTION 
 
The significance of atrial fibrillation (AF) as a major public health problem comes from its 
increasing prevalence and strong association with morbidity and mortality.1,2 Patients with AF 
have 5 times the risk of stroke and double the risk of mortality compared with those without 
AF.3,4 AF has known to complicate acute myocardial infarction (MI).5 In addition to being an 
established complicating factor for MI, recent studies have revealed that AF increased the risk of 
MI.6,7 In the Atherosclerosis Risk in Communities (ARIC) study, AF was associated with an 
increased risk of non-ST segment elevation MI (NSTEMI), especially in women.6 In the Reasons 
for Geographic and Racial Difference in Stroke (REGARDS) study, AF was associated with a 70% 
increased risk of incident MI, the risk being higher in women than in men and in blacks than in 
whites.7 However, the risk of MI in association with AF in the general population has not been 
previously investigated, and the mechanisms explaining these associations are yet to be validated. 
Thus, we examined the association between AF and MI by analyzing a recently developed 
Korean National Health Insurance Service–national sample cohort (NHIS-NSC) database, which 
includes over five hundred thousand individuals. In addition, the beneficial effects of the 
commonly prescribed medications for AF patients on the occurrence of MI have not been 
elucidated. Herein, we also analyzed the association of medications with incident MI in AF 
patients.  
 
II. MATERIALS AND METHODS 
 
1. Source of study data 
The national health insurance service (NHIS) in Korea is a single-payer program and is 
mandatory for all residents in South Korea.8 All Koreans residing in South Korea are covered 
under medical coverage of NHIS, which includes the following three categories: employee 
insured, self- employed insured, and medical aid beneficiary.9 The NHIS database represents the 
entire Korean population.10 The NHIS released the National Sample Cohort database in 2015. It 
consists of 1,025,340 Koreans as an initial 2002 cohort and follows the subjects through 2013. 
This represents about 2.2% of the source population in 2002 (46,605,433). This is a semi-
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dynamic cohort database; the cohort has been followed up to either the time of the participant’s 
disqualification of health services due to death or emigration or the end of the study period. The 
database contains eligibility and demographic information regarding health insurance and 
medical aid beneficiaries, medical bill details, medical treatment, disease histories, and 
prescriptions.  
In this cohort, the subjects’ disease information was classified according to the 10th revision of 
the International Classification of Diseases (ICD-10) codes obtained from the Korean National 
Statistical Office (Supplementary table 1). This study was approved by the Institutional Review 
Board (IRB) of Yonsei University College of Medicine in Seoul, Korea. The IRB waived the 
requirement to obtain informed consent, and this study was conducted in accordance with the 
tenets of the Declaration of Helsinki. 
 
2. Study population 
A total of 506,805 patients, who had a health check-up between 2009 and 2013, were enrolled 
and follow-up data were reviewed until December 2014. AF cases were identified by ICD-10 
codes of I48.11 Valvular AF cases, which were defined from any diagnoses or operation of mitral 
stenosis (ICD-10: I05.0, I05.2, I34.2, Z95.2-4), were excluded. To ensure accuracy of diagnosis, 
we defined patients as AF only when it was a discharge diagnosis or was confirmed more than 
twice in the outpatient department. To further evaluate the accuracy of the definition of AF, a 
validation study was performed in 628 randomly selected patients with ICD-10 code of I48 in 2 
separate hospitals. Their electrocardiograms (ECGs) were reviewed by two physicians. Patients 
were determined to have AF if documented by ECG. The positive predictive value was 94.1%. 
The clinical end point was the first occurrence of MI during follow up. MI cases were identified 
by ICD-10 codes of I21or I22, and were ascertained when the diagnosis was confirmed by 
hospitalization or death from MI. To evaluate the accuracy of our definition of MI, we conducted 
a validation study with medical records of two independent tertiary hospitals from 2006-2013. A 
total of 4,688 patients were found to have ICD codes of I21 or I22. Data of clinical history, 
cardiac biomarkers, ECGs and the results of coronary angiography were reviewed by two 
cardiologists. The positive predictive value was 86.5%.  
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Supplementary table 1. International Classification of Disease 10th codes for comorbidities 
Diagnosis of Comorbidities 
Atrial fibrillation Defined from diagnosis* ICD10: I48 
Ischemic stroke Defined from diagnosis* ICD10: I63, I64 
Heart failure Defined from diagnosis* ICD10: I11.0, I50, I97.1 
Diabetes mellitus Defined from diagnosis* 
ICD10: E10, E11, E12, E13,   
E14 
Hypertension Defined from diagnosis* ICD10: I10, I11, I12, I13, I15 
Myocardial infarction Defined from diagnosis* I21, I22, I25.2 
Peripheral arterial obstructive  
disease 
Defined from diagnosis* 
ICD10: I70.0, I70.1, I70.2, I70.8, 
I70.9, I73.9, I79.2 
Dyslipidemia Defined from diagnosis* ICD10: E78 
Chronic obstructive lung 
disease 
Defined from diagnosis* J42, J43(except J43.0), J44 
Chronic renal failure Defined from eGFR eGFR <60 mL/min per 1.73 m2 
End state renal disease 
Defined from national  
registry for severe illness. 
Patients with ESRD undergoing 
chronic dialysis or received a 
kidney transplant. 
Malignancy 
Defined from diagnoses  
of cancer (non-benign) 
ICD10: C00-C97 
Potential absence of  
non-valvular  
atrial fibrillation 
Defined from any  
diagnoses or operation  
of mitral stenosis 
ICD10: I05.0, I05.2, I34.2,  
Z95.2-4 
Chronic Liver disease 
Defined from diagnosis  
of  chronic liver disease,  
cirrhosis, and hepatitis 
ICD10: B18, K70, K71, K72,  
K73, K74, K76.1 
*To ensure accuracy, comorbidities were established based on one inpatient or two        
outpatient records of ICD-10 codes in the database. 
 
Of the 8,296 patients with AF, patients who had AF or MI before 2009 (n=4,976) and who 
suffered an MI before AF (n=25) were excluded. Finally 3,295 patients were enrolled in the AF 
group. Among those without AF (n=498,509), 494,071 patients were enrolled in the no-AF group 
after excluding the patients who suffered an MI before 2009 (n=4,438). Given the differences in 
the baseline characteristics and the risk of cardiovascular diseases between the AF and control 
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groups, we used 1:4 propensity score matching and calculated the propensity score, with 
predicted probability of AF occurrence conditional on baseline covariates, by multivariable 
logistic regression (Table 1).12 We attempted to match each patient in the AF cohort with a patient 
in the control cohort with a similar propensity score, based on nearest-neighbor matching without 
replacement, using a caliper width equal to 0.05 of the standard deviation of the logit of the 
propensity score. Pre- and post-match absolute standardized differences were presented as Love 
Plots.13  
The following variables were entered: age, sex, and a history of congestive heart failure, 
hypertension, diabetes mellitus, chronic kidney disease (CKD) or end-stage renal disease (ESRD), 
dyslipidemia, ischemic stroke, peripheral artery occlusive disease (PAOD), chronic obstructive 
pulmonary disease (COPD), history of malignancy, anemia, smoking history, blood pressure, 
body mass index, waist circumference, body surface area, cholesterol level, serum creatinine, and 
estimated –glomerular filtration rate (eGFR). Covariates included in propensity matching were 
the data from baseline examination, and the definition of comorbidity was based on ICD codes. 
The matching procedure was performed using R packages (R Foundation for Statistical 
Computing, Vienna, Austria), including Matchit, RItools, and CEM.14 Finally, a total of 3,295 AF  
patients and 13,159 no-AF patients were evaluated in this study (Figure 1).  
 
Figure 1. Study population. AF, atrial fibrillation; MI, myocardial infarction; NHIS HCK, National 
Health Insurance Service-health check-up. Medical records of all participants were reviewed from 2002 till 
2013. 
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3. Statistical analysis  
Data were presented as mean ± SD for normally distributed continuous variables and as 
proportions for categorical variables. Age-adjusted incidence rate of MI per 1000 person-years in 
patients with and without AF was calculated in the propensity matched population and in the sex 
subgroup. Person-time for the incidence rate in the AF group was calculated from AF diagnosis to 
the occurrence of MI or censoring. The exclusion method was used to account for the guarantee-
time bias in the AF group.15 In the no-AF group, person-time was calculated from baseline to MI 
occurrence or censoring. Cumulative incidence of MI was plotted using a Kaplan-Meier method, 
with statistical significance examined using log-rank test by AF status. The risk of MI was 
assessed using Cox regression analysis. Statistical analysis was performed using SPSS 21.0 
statistical software (SPSS Inc., Chicago, IL, USA). All p-values were two tailed, and values less 
than 0.05 were considered statistically significant. 
 
III. RESULTS 
 
1. Baseline characteristics  
The mean age of matched patients was 63 years (range, 19-98 years) and 58% of the patients 
were male. Table 1 shows the baseline characteristics of the study population stratified by AF 
status. In the full pre-match cohort, patients with AF were older, had a higher body mass index, a 
higher prevalence of heart failure (HF), hypertension, diabetes, CKD or ESRD, dyslipidemia, 
ischemic stroke, PAOD, and COPD (all P<0.001). Mean CHA2DS2-VASc score was 2.6 ± 1.9 in 
the AF group and 1.2 ± 1.3 in the no-AF group (P<0.001). Covariates with significant imbalances 
in the pre-matched cohort which were well balanced after propensity matching are displayed in 
Table 1. Absolute standardized differences in all measured covariates were less than 5%, 
suggesting substantial covariate balance across the groups (Figure 2).  
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Table 1. Baseline characteristics by AF status before and after propensity score matching  
AF, atrial fibrillation; CHADS2, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke; 
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR-CKD-EPI, estimated 
glomerular filtration rate-chronic kidney disease-epidemiology collaboration; ESRD, end–stage renal disease; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; PAOD, peripheral artery obstructive disease; VASc, 
Vascular disease, age 65-75 years, sex category 
 
 Before propensity matching  After propensity matching 
 No AF  
(n=494,071) 
AF  
(n=3,295) 
Standard, 
mean, 
Difference 
p No AF  
(n=13,159) 
AF  
(n=3,295) 
Standard, 
mean, 
Difference 
Age, years 47.4±14.2 62.8±12.9 1.194 <0.001 62.9±12.9 62.8±12.9 -0.006 
Female, % 50.1 42 -0.173 <0.001 42.1 42.0 -0.003 
Systolic BP, mmHg 122.1±15.3 128.3±16.9 0.366 <0.001 128.5 ±16.1 128.3 ±16.8 -0.012 
Diastolic BP, mmHg 76.0±10.2 78.6±10.6 0.245 <0.001 78.8 ±10.2 78.6 ±10.7 -0.012 
Body mass index, kg/m2 23.7±3.3 24.3±3.4 0.190 <0.001 24.3 ±3.2 24.3 ±3.4 0.003 
Waist circumference, cm  79.9± 9.3 83.9± 9.1 0.449 <0.001 84.0 ±8.6 84.0 ±9.1 0.003 
Heart failure, % 1.9 11.5 0.299 <0.001 10.1 11.5 0.038 
Hypertension, % 20.7 57 0.732 <0.001 56.5 57 0.009 
Diabetes, % 12.3 32.1 0.426 <0.001 31.3 32.1 0.017 
CKD or ESRD, % 5.6 17.3 0.309 <0.001 16.6 17.3 0.015 
Dyslipidemia, % 18.6 38.1 0.400 <0.001 38.2 38.1 -0.003 
Ischemic stroke, % 2.4 9.3 0.239 <0.001 9.1 9.3 0.005 
PAOD, % 6.9 19.4 0.315 <0.001 19.2 19.4 0.005 
COPD, % 6.0 17.3 0.298 <0.001 16.6 17.3 0.015 
History of malignancy, % 6.6 14.1 0.218 <0.001 13.7 14.1 0.011 
Anemia, % 11.8 16.7 0.245 <0.001 16.3 16.2 -0.004 
Smoking, % 37.6 39.4 0.021 0.042 38.4 39.4 0.004 
Total cholesterol, mg/dl 195.1±37.2 192.9±39.4 -0.054 0.001 192.9 ±37.8 192.9 ±39.3 0.002 
Triglyceride, mg/dl 131.9±94.1 139.2±88 0.088 <0.001 139.6 ±86.7 139.2 ±88.2 -0.004 
HDL-cholesterol, mg/dl 56.5±27.9 55.1±36.5 -0.028 0.025 54.8 ±35.3 55.1 ±36.5 0.006 
LDL-cholesterol, mg/dl 113.8±37.6 112.4±38.7 -0.031 0.038 112.8 ±38.8 112.4 ±38.7 -0.007 
Serum creatinine, mg/dl 1.0±1.1 1.1±1.2 0.079 <0.001 1.09 ±1.2 1.10 ±1.2 0.007 
eGFR-CKD-EPI 89.5±21.1 76.7±21.1 -0.601 <0.001 77.4 ±20.5 77.1 ±20.9 -0.010 
CHADS2 0.5 ± 0.9 1.4 ± 1.4 0.995 <0.001 1.4 ± 1.4 1.4 ± 1.4 0.029 
CHA2DS2-VASc 1.2 ± 1.3 2.6 ± 1.9 1.073 <0.001 2.5 ± 2.0 2.6 ± 2.0 0.026 
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Figure 2. Love plots for absolute standardized difference for baseline covariate between patients 
with and without atrial fibrillation, before and after propensity score matching. CKD, chronic kidney 
disease; ESRD, end–stage renal disease; PAOD, peripheral artery obstructive disease; COPD, 
chronic obstructive pulmonary disease; BP, blood pressure; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; eGFR-CKD-EPI, estimated glomerular filtration rate-chronic kidney 
disease-epidemiology collaboration 
 
Aspirin, oral anticoagulants (OACs), statin, digoxin, beta blocking agent (BB), and calcium 
channel blocker (CCB) were more frequently prescribed in AF patients; aspirin (50.3% vs. 27.5%, 
P<0.001), anticoagulant (20.9% vs. 0.3%, P<0.001), statin (38.2% vs. 28.5%, P<0.001), digoxin 
(13.4% vs. 0.9%, P<0.001), BB (43.1% vs.16.1%, P<0.001), and CCB (11.4% vs. 2.5%, P<0.001). 
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2. AF and the risk of MI 
Over 4.2 years of follow up, 137 MI events occurred. The mean ± SD time from AF diagnosis to MI 
in those with AF was 4.1 ± 1.0 years (median, 3.9 years). Figure 3 shows the unadjusted cumulative 
incidence of MI stratified by baseline AF status in the entire cohort (Figure 3A) and the matched 
cohort (Figure 3B). Patients with AF had a higher incidence of MI than those without AF in both the 
entire cohort and the matched cohort (log rank p<0.001 for both cohorts). 
 
 
Figure 3. Unadjusted cumulative incidence of myocardial infarction by baseline atrial fibrillation 
(AF) status in the entire cohort (A) and in the propensity scored matched cohort (B). 
The age adjusted incidence rate of MI among participants was higher in those with AF than in 
those without AF (4.42 vs 1.42 per 1000 person-years), with an incidence rate ratio (IRR) of 3.12 
[95% CI, 2.23-4.36]. In a sex stratified analysis, IRR of age-adjusted MI stratified by AF status was 
higher in women (IRR, 3.65; 95% CI, 2.09-6.38) than in men (IRR, 2.88; 95% CI, 1.89-4.39) 
(Figure 4). 
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Figure 4. Age-adjusted incidence rate and incidence rate ratios of myocardial infarction by atrial 
fibrillation (AF) status. *Age adjusted incidence rate and incidence rate ratios were based on the 
average of the cohort. 
 
In a Cox proportional hazards model of the matched cohort, AF was an independent risk factor for 
MI [Hazard ratio (HR), 3.12; 95% CI, 2.23-4.37, p<0.001]. Other risk factors were hypertension 
(HR, 1.87; 95% CI, 1.30-2.69, p<0.001), diabetes (HR, 1.79; 95% CI, 1.28-2.51, p<0.001), HF (HR, 
2.04; 95% CI, 1.32-3.14, p=0.003), CKD or ESRD (HR, 2.70; 95% CI, 1.09-3.85, p<0.001), and 
dyslipidemia (HR, 1.45; 95% CI, 1.04-2.03, p=0.031) (Table 2).  
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Table 2.  The independent clinical predictors of myocardial infarction in propensity score matched 
cohort  
 HR 95% CI p-value  
Age, per 1 year  1.05 1.03-1.07 <0.001 
Atrial fibrillation 3.12 2.23-4.37 <0.001 
Heart failure 2.04 1.32-3.14 0.003 
Hypertension 1.87 1.30-2.69 <0.001 
Diabetes 1.79 1.28-2.51 <0.001 
CKD or ESRD 2.70 1.90-3.85 <0.001 
Dyslipidemia 1.45 1.04-2.03 0.031 
Ischemic stroke 1.71 1.05-2.77 0.030 
COPD 2.18 1.51-3.15 <0.001 
Anemia 1.54 1.02-2.30 0.038 
Waist circumference  1.03 1.01-1.05 0.011 
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end stage 
renal disease 
 
3. Association of AF with MI in subgroups  
The associations of AF with MI among various subgroups of patients are displayed in Figure 5. The 
risk of hospitalization or death due to MI was significantly higher in the AF group than in the no-AF 
group, regardless of age (p for interaction=0.1), sex (p for interaction=0.6), comorbidities with HF 
(p for interaction=0.11), and CKD or ESRD (p for interaction=0.56) at baseline. On the other hand, 
we found that the risk of AF associated incident MI was higher in patients free of hypertension [HR, 
7.87 (95% CI, 4.13-15.0) vs. 2.06 (95% CI, 1.35-3.14), p for interaction=0.001], diabetes [HR, 4.89 
(95% CI, 3.13-7.67) vs. 1.66 (95% CI, 0.72-3.84), p for interaction=0.003], ischemic stroke [HR, 
3.50 (95% CI, 2.44-5.03) vs. 1.407 (95% CI, 0.51-3.91), p for interaction=0.002], and dyslipidemia 
[HR, 4.49 (95% CI, 2.84-7.09) vs. 1.98 (95% CI, 1.18-3.35), p for interaction=0.021] at baseline.  
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Figure 5. Association of atrial fibrillation with hospitalization or death due to myocardial infarction 
in subgroups of propensity score matched cohort. 
 
4. Risk of MI in association with medications in AF patients  
Medications analyzed in this study were aspirin, OACs, statin, digoxin, BB and CCB. 
Anticoagulants included in the analysis were warfarin, direct thrombin inhibitor and factor Xa 
inhibitors. 
Figure 6 shows the effect of OACs on the occurrence of MI in AF patients. OACs were prescribed 
in 688 of the 3,295 AF patients and cumulative incidence of MI was lower in AF patients on OACs 
than in those without OACs (Figure 6A, p=0.004). Subgroup analyses were conducted to focus on 
the effects of OACs according to CHA2DS2-VASc scores. In patients with AF with a CHA2DS2-
VASc score of 0 or 1 (n=1,191), OACs were prescribed in 213 (17.9%) patients and cumulative 
incidence of MI did not significantly differ between the patients on OACs and no OACs (Figure 6B, 
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p=0.385). In patients with CHA2DS2-VASc ≥ 2 (n=2,104), OACs were prescribed in 475(22.6%) 
patients and cumulative incidence of MI was significantly lower in patients on OACs than in no 
OCAs. (Figure 6C, p=0.004). 
 
  
Figure 6. The effect of oral anticoagulants on the occurrence of atrial fibrillation (AF) associated 
myocardial infarction. In all AF patients (A), in patients with CHA2DS2-VASc score of 0 or 1 (B), 
and in patients with CHA2DS2-VASc score ≥ 2 (C). 
 
Statins were prescribed in 1,259 of the 3,295 AF patients cumulative incidence of MI was lower 
in AF patients on statin than in those without statin (Figure 7A, p=0.039). Aspirin users showed a 
similar trend, which did not reach statistical significance (Figure 7B, p=0.058). The most commonly 
prescribed rate control agent was BB, followed by digoxin and CCB. MI events did not differ 
between patients who were taking digoxin (Figure 7C), BB (Figure 7D), and CCB (Figure 7E) and 
those who were not taking these medications. Overall death, regardless of the mode of death, 
occurred more often in patients with MI than in those without MI during the follow up period (35.8% 
vs 4.6%, p<0.001). 
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Figure 7. Risk of incident myocardial infarction associated with medication in patients with atrial 
fibrillation. 
 
IV. DISCUSSION 
 
1. Main findings 
In this study from NHIS, a nationwide population based cohort, our principal findings are as follows: 
(1) AF was significantly associated with increased risk of incident MI. (2) Association between AF 
and the risk of MI did not differ by sex. (3) The risk of AF associated incident MI was higher in 
patients free of hypertension, diabetes, ischemic stroke, and dyslipidemia, which were well known 
risk factors for MI. (4) The incidence of AF associated incident MI was lower in patients on 
anticoagulant and statin therapies.  
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2. AF and the risk of MI 
In this study, AF was associated with an increased risk of MI in both the entire cohort and the 
propensity matched cohort. In the time dependent Cox analysis using survival time from 2009 to the 
occurrence of MI, the risk of AF associated incident MI was similar (HR, 3.02; 95% CI, 2.17-4.41, 
p<0.001). The well-known risk factors and potential confounders for MI were included in the 
matching and the association was stronger in women than in men. These findings were in 
accordance with the recently reported findings in the REGARDS and ARIC studies which showed 
AF as an independent risk factor for MI, with sexual and racial differences.6,7,16 In another study, 
association between AF and inflammation has been reported.17 The well-known pathophysiology of 
MI is plaque rupture in atherosclerotic coronary arteries and subsequent thrombus formation in 
infarct related arteries. A number of histologic observations have shown that a ruptured plaque 
contains more inflammatory cells and activated in the vessel wall.18 These findings may shed light 
on similar underlying mechanisms in both AF and MI. Our observation that there is a higher AF-
associated risk of MI in women than in men provides evidence for gender difference in 
cardiovascular disease outcomes and the potential differences in the impact of risk factors among 
sexes. It is less likely that sex difference in MI occurrence was confounded by the difference in AF-
associated co-morbidities because we adjusted for the potential confounders in propensity matching 
as covariates.  
 
3. Association of AF with MI in subgroups  
Notably, we confirmed that the risk of MI was significantly higher in patients with AF free of overt 
cardiovascular disease-hypertension, diabetes, ischemic stroke, and dyslipidemia-than in subjects 
without AF. Previous study from Olmsted County revealed that lone AF in the absence of overt 
cardiovascular disease has a benign clinical course with a comparable risk of embolic events and 
mortality to the general population.19,20 In contrast, recent studies from Brand and Chao showed that 
patients with AF without cardiovascular co-morbidities had an increased risk of cardiovascular 
events and mortality.21,22 These interactions with established risk factors for MI suggest that shared 
underlying risk factors for MI is not the only mechanisms explaining the association between AF 
and MI. There are plausible explanations for why AF patients with less co-morbidity were 
predisposed to MI. In high risk patients, who already have established risk factors for MI, AF may 
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contribute less to the occurrence to MI, compared with those who were previously healthy. In our 
study, anticoagulants showed beneficial effect against AF associated incident MI, especially in 
patients with CHA2DS2-VASc score ≥ 2. Accordingly, embolic events to coronary arteries are 
another possible explanation. Statin use, and also, is higher in patients with established 
cardiovascular diseases, which may decrease the incident MI. Further study is needed in this regard. 
 
4. Risk of MI in association with medications in AF patients 
In this analysis stratified by medications after AF diagnosis, the risk of incident MI was less in 
anticoagulant users. Previously, it was reported that warfarin might have a protective effect against 
MI after acute coronary syndrome.23 The pathophysiology and pharmacokinetics related to the 
protective effect of warfarin against MI in AF patients have not been fully understood. Even though 
the actual incidence of coronary embolism is not known and it is considered to be rare, sporadic 
cases of thromboembolic MI have been reported in patients with AF.24,25 Prizel et al.26 reported that 
AF was the underlying disease predisposing to coronary embolism in 24% of these cases. Prevention 
of thrombus formation with use of warfarin, in part, might be a plausible explanation for the 
beneficial effect against MI in AF patients. In our study, the anticoagulants analyzed were direct 
thrombin inhibitor, factor Xa inhibitors, as well as warfarin, and the protective effect of each 
medication against AF-associated MI was not evaluated. Further investigation is needed.  
Clinical trials have already demonstrated a clear beneficial effect of statin for primary and 
secondary prevention of coronary heart disease.27,28 In accordance with these studies, this study 
revealed that the risk of AF-associated incident MI was less in statin users than in non-users.  
Type 2 MI can occur due to the episode of poorly controlled ventricular response in AF 
patients.29 The rate control strategy in AF patients is expected to reduce the occurrence of type 2 MI, 
by reducing the oxygen demand and by increasing the diastolic filling time of coronary arteries. 
However, the result of this study was not in accordance with this common belief, suggesting that 
type 2 MI is less likely to be the main mechanism by which AF leads to MI.  
 
5. Clinical implications 
Our study revealed that AF increased the risk of MI. Considering MI as a known risk factor for AF,30 
this result suggests a bidirectional relationship between AF and MI. The possible explanation for this 
16 
 
bidirectional relationship comes from the fact that AF and MI share similar risk factors. The 
pathophysiology of AF is complex and incompletely understood. An association between AF and 
abnormal prothrombotic plasma markers suggests that arrhythmia itself may contribute to the 
development of pro-thrombotic status.31 Recently, it was reported that various inflammatory markers 
such as C-reactive protein, tumor necrosis factor-α, and interleukins are related to the presence or 
the outcome of AF.17 In our study, anticoagulants and stain showed beneficial effects against incident 
MI in AF patients. It is conceivable that the antithrombotic effect of anticoagulants and the anti-
inflammatory effect of statin contributed to the favorable outcome.  
The prevalence of AF doubles with each additional decade of life.32 With an increasing older 
population, the occurrence of AF itself and AF-associated morbidity and mortality is expected to 
increase as well. From a preventive perspective, the notion should suggest that AF potentiates the 
risk of MI. In addition, genetic difference and socioeconomic status of those who are predisposed to 
MI should be investigated further. 
 
6. Limitations 
There are several limitations to this study. Although we ascertained AF cases with ECGs as well as 
ICD codes, it is possible that paroxysmal or asymptomatic AF cases were not detected. Also, we 
could not analyze paroxysmal, persistent and permanent AF separately. Second, because MI cases 
were identified by ICD-10 code, data for cardiac markers, ECGs, and coronary angiography were 
not available, which could have provided further information about the type of MI.29 We could not 
analyze the association of AF with different types of MI. Third, even though the NHIS recommends 
biennial health check-up to all health insurance subscribers, it is not compulsory and there is a 
possibility that healthier and more educated subjects could have participated in this study. Fourth, 
potentially uncontrolled covariates may exist because comorbidities included in propensity matching 
are the data from baseline examination. They may be absent at baseline, but may have developed 
during the follow-up. Fifth, similar to other studies, considerable confounders may remain although 
propensity-score matching was well balanced. Despite the limitations, this study is the nation-wide 
cohort based observational studies providing the further evidence for a link between AF and MI, and 
the effects of medications on the occurrence of AF related incident MI. 
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V. CONCLUSION 
AF is associated with an increased risk of MI in the Korean population, with the age adjusted 
incidence rate of MI being higher in women than in men. Anticoagulants and statin showed 
beneficial effects against MI in AF patients. Our finding suggests that AF complications beyond 
stroke should extend to total mortality to include MI. 
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ABSTRACT(IN KOREAN) 
 
심방세동과 연관된 심근경색의 위험성 
: 성향점수 매칭을 통한 전국적 코호트 연구 
 
<지도교수 정보영> 
 
연세대학교 대학원 의학과 
 
이 혜 영 
 
목적 : 심방세동은 심근경색 환자에서 그 예후에 좋지 않은 영향을 미치는 요인으로 
이미 알려져 있다. 최근 연구에서 심방세동이 심근경색의 위험을 높인다고 보고한 바 
있다. 본 연구는 심방세동과 연관된 심근 경색의 위험도를 전체 인구를 대상으로 하여 
조사하고자 하였다 
방법 : 한국 국민건강보험 자료를 분석하여 기존에 심방세동이나 심근경색의 기왕력이 
없는 497,366 명(평균연령 47.6 세, 250,569 여성)을  5 년간 추적 관찰하였으며 이 
기간동안  심방세동이 새로 발생한 3,295 명과 성향점수 매칭으로 선별된 심방세동이 
없는 13,159명을 대상으로 심근경색 발생율을 비교 분석하였다. 
결과 : 4.2 년의 추적관찰 기간 동안 총 137 건의 심근경색이 발생하였으며 심방세동 
진단시점에서 심근경색 발생까지의 기간은 4 년이었다. 연령 보정 심근경색 발생율은 
심방세동이 있는 군에서 그렇지 않은 군보다 더 높았다 [발생율, 4.42 (95% 신뢰구간; 
3.25-5.98 대 1.42 (95% 신뢰구간. 1.07-1.87)/1000 인년]. 심방세동은 심근경색 발생 
위험을 3 배 증가시키며 [위험비율, 3.25 (95% 신뢰구간; 2.24-4.7), 추적 기간 동안 
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심근경색의 누적 발생율은 항응고제와 지질 강하제를 복용한 군에서 그렇지 않은 군에 
비해 유의하게 작았다.  
결론 : 심방세동은 심근경색의 위험을 증가시키며, 그 위험도는 항응고제와 지질 
강하제의 사용에 의해 감소된다. 본 연구의 결과는 심방세동의 합병증이 뇌졸중뿐만 
아니라 심근경색에 의한 사망률까지 고려해야 함을 시사한다. 
핵심되는 말 : 심방세동, 심근경색, 전국민 코호트 
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